MOTS-c Dosage Guide: Protocols, Calculator & Safety

Beginner protocol:

• Dose: 5 mg subcutaneous
• Frequency: 2x weekly
• Timing: Morning, fasted if possible (aligns with natural AMPK activation cycles)
• Duration: 8-12 weeks initial protocol to assess response

Reconstitution: Typical 10 mg vial + 2 mL BAC water = 5 mg/mL. A 5 mg dose = 1 mL = 100 units on U-100 insulin syringe (larger volume — may require splitting into two injections or using a larger syringe).

Alternative reconstitution for smaller volumes:

• 10 mg + 1 mL BAC water = 10 mg/mL
• 5 mg dose = 0.5 mL = 50 units

Schedule options:

Option A — Twice-weekly:

• Monday morning: 5 mg SC
• Thursday morning: 5 mg SC
• Rest of week: no dosing

Option B — Three-times-weekly (more intensive):

• Monday/Wednesday/Friday mornings: 5 mg SC
• Rest of week: no dosing

Why intermittent dosing: MOTS-c is a signaling peptide, not a chronic replacement therapy. Endogenous MOTS-c is released in pulses associated with metabolic stress (exercise, fasting). Replicating intermittent signaling rather than continuous exposure is more pharmacologically appropriate and limits any potential mTOR-suppression concerns from sustained AMPK activation.

Timing with exercise:

Some users time MOTS-c dosing to training days for synergistic AMPK effect:

• Morning of hardest training day: 5 mg SC pre-workout or early AM
• Rationale: MOTS-c amplifies the AMPK signal that exercise produces; combination may enhance training adaptations

First-use considerations:

• Monitor for any hypoglycemic symptoms during first 2-3 doses
• Maintain normal dietary carb intake during first week
• Expect possible mild fatigue in first week as metabolic adaptation occurs
• Note any subjective changes in energy, recovery, or exercise capacity

Labs to run before starting:

• Fasting insulin, fasting glucose, HbA1c
• Comprehensive metabolic panel
• Lipid panel
• Baseline body composition (DEXA or calipers + weight)

Recheck at week 8 and week 12.

Intermediate protocol:

• Dose: 10 mg subcutaneous
• Frequency: 2-3x weekly
• Timing: Morning, fasted, ideally on training days
• Duration: Ongoing with periodic assessment

Escalation rationale:

After 8-12 weeks at 5 mg 2x weekly, users who have experienced positive metabolic effects (improved insulin sensitivity on labs, improved exercise capacity, body composition shifts) can escalate to 10 mg 2-3x weekly for more robust signaling.

Optimized schedule for athletic users:

• Day 1 (hard training day): 10 mg SC in morning, fasted
• Day 3 (recovery or moderate training): 10 mg SC in morning
• Day 5 (hard training day): 10 mg SC in morning
• Rest days: no dosing

This pattern aligns MOTS-c signaling with training stress for maximum adaptive benefit while maintaining intermittent exposure.

Schedule for longevity/metabolic optimization (non-athletes):

• Monday/Thursday: 10 mg SC in morning
• Continue indefinitely with quarterly lab monitoring

Stacking considerations at intermediate level:

MOTS-c stacks sensibly with:

• NAD+ precursors (NMN, NR) — complementary mitochondrial support
• Urolithin A — mitophagy activator; enhances mitochondrial quality control
• Metformin — same pathway (AMPK); usually not needed to combine (redundant) but not contraindicated at appropriate doses
• BPC-157 — non-interfering; different pathway
• CJC-1295 + ipamorelin — non-interfering GH axis support

MOTS-c should be used with caution alongside:

• Aggressive anabolic protocols (testosterone, IGF-1 LR3, heavy MK-677 use) — the AMPK/mTOR opposition may blunt muscle-building signals
• Insulin or sulfonylureas — theoretical additive hypoglycemic risk

Monitoring during intermediate use:

• Quarterly: fasting insulin, fasting glucose, HbA1c
• Semi-annually: lipid panel, CMP, CBC
• Annually: full physical with body composition assessment

Track subjective markers including energy, exercise capacity, body composition, sleep quality, and metabolic flexibility (ability to use fat and carbs as fuel alternately).

Advanced protocol considerations:

Advanced MOTS-c use involves integration with broader metabolic optimization and longevity protocols rather than significant dose escalation. The dose ceiling is reached around 10 mg per injection — beyond this, no additional benefit has been documented, and the signaling system appears to saturate.

Advanced metabolic/longevity stack:

• MOTS-c: 10 mg SC 2-3x weekly
• NAD+ precursor (NMN 500-1000 mg daily or NAD+ injection 100-200 mg 2x weekly)
• Urolithin A 500-1000 mg daily (mitophagy)
• Resveratrol or pterostilbene 250-500 mg daily (SIRT1)
• Optional: Rapamycin 5-8 mg weekly (mTOR inhibition for longevity)
• Exercise: Cornerstone — MOTS-c works with exercise, not replacement of it

This stack targets multiple longevity pathways simultaneously (AMPK, SIRT1, mitophagy, mTOR regulation, mitochondrial biogenesis) with the understanding that no single intervention is sufficient for meaningful longevity effect.

Situations where MOTS-c is particularly well-suited:

• Metabolic syndrome or pre-diabetes — insulin sensitivity improvement is a primary effect
• Age-related fatigue and reduced exercise capacity — exercise-mimetic properties restore function
• Reduced mitochondrial function (suggested by CoQ10 deficiency, lactic acidosis sensitivity, exercise intolerance) — direct mechanistic fit
• Post-illness or post-injury recovery with deconditioning — metabolic reset

Situations where MOTS-c is less ideal:

• Active aggressive muscle-building phase — AMPK/mTOR antagonism may blunt hypertrophy signal
• Caloric deficit with aggressive lifting — compounding energy-restriction signals
• Concurrent metformin at high doses — redundant AMPK activation; choose one
• Pregnancy, active malignancy, children/adolescents — insufficient data

Monitoring for advanced long-term users:

• Quarterly comprehensive metabolic panel
• Semi-annual HbA1c, lipid panel, inflammatory markers
• Annual body composition (DEXA preferred)
• Annual comprehensive physical exam
• Periodic mitochondrial function markers (lactate clearance, VO2max if athletic)

Combinations to avoid:

• MOTS-c + direct AMPK activators at high doses (high-dose metformin + berberine + MOTS-c) — potentially excessive AMPK activation with unpredictable effects
• MOTS-c + aggressive keto/PSMF during prolonged fasting — all AMPK-activating mechanisms stacked; theoretical concern about over-activation

Discontinuation triggers:

• Persistent fatigue beyond the initial adaptation period
• Any new or worsening symptoms possibly attributable to MOTS-c
• Pregnancy (immediate discontinuation)
• New diagnosis of malignancy (pause until oncology evaluation)